School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Anticancer Drugs. 2024 Jan 1;35(1):36-45. doi: 10.1097/CAD.0000000000001543. Epub 2023 Sep 11.
The human CXCR3 receptor was initially identified and cloned in the mid-1990s. In the process of understanding CXCR3, it gradually found that it plays an important role in the process of a variety of diseases, including inflammation, immune diseases, cancer, cardiovascular diseases, central nervous system diseases, etc., which attracted the attention of many researchers. Subsequently, some small molecule inhibitors targeting CXCR3 receptors were also developed. Unfortunately, no CXCR3 inhibitors have been approved for marketing by FDA. Up to now, only one CXCR3 small molecule inhibitor has entered the clinical trial stage, but it has not achieved ideal results in the end. Therefore, there is still much to think about and explore for the development of CXCR3 inhibitors. This article reviews the important role of CXCR3 in various physiological and pathological processes and some small molecule inhibitors of CXCR3.
人类 CXCR3 受体最初于 20 世纪 90 年代中期被发现并克隆。在了解 CXCR3 的过程中，逐渐发现它在多种疾病的发生发展过程中发挥着重要作用，包括炎症、免疫性疾病、癌症、心血管疾病、中枢神经系统疾病等，这引起了众多研究人员的关注。随后，一些针对 CXCR3 受体的小分子抑制剂也被开发出来。遗憾的是，目前 FDA 尚未批准任何 CXCR3 受体抑制剂上市。迄今为止，仅有一种 CXCR3 小分子抑制剂进入临床试验阶段，但最终并未取得理想的结果。因此，对于 CXCR3 抑制剂的开发仍有许多值得思考和探索的地方。本文综述了 CXCR3 在多种生理和病理过程中的重要作用，以及一些 CXCR3 的小分子抑制剂。
